BioSpace News Archive

FDA

Tabrecta: FDA Gives Novartis Approval for First-Ever Therapy for NSCLC Tumors with METex14

Developed by Novartis, the drug, Tabrecta, is designed for a type of NSCLC that has spread to other parts of the body and cannot be removed by surgery.

May 6, 2020
·
4 min read
·
Gail Dutton
Deals

Number of Shares and Voting Rights of Innate Pharma as at May 1, 2020

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities charter, Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as at May 1, 2020

May 6, 2020
·
4 min read
Deals

Silk Road Medical Announces Pricing of Upsized Public Offering - May 06, 2020

Silk Road Medical, Inc. announced the pricing of an underwritten public offering of 6,808,154 shares of its common stock at a public offering price of $39.00 per share, before deducting underwriting discounts and commissions.

May 6, 2020
·
4 min read
Drug Development

Targovax Announces That Abstract on Interim Phase I Clinical Data From the Phase I/II Peritoneal Trial is Accepted at ASCO

Targovax ASA announces that interim phase I clinical data from the phase I/II trial evaluating systemic durvalumab + intraperitoneal ONCOS-102 in patients with peritoneal disease originating from ovarian or colorectal cancer, will be presented at the ASCO20 Virtual Scientific conference, 29-31 May 2020.

May 6, 2020
·
1 min read
Policy

Relief Therapeutics Holding (RLF:SIX) Drug Aviptadil Enters FDA Trial at NYU Langone Health, New York, to Treat COVID-19-Induced Acute Respiratory Distress

Aviptadil targets the cytokine storm that causes fatal Respiratory Distress in COVID-19

May 6, 2020
·
4 min read
Drug Development

Galecto Advances Phase 2b Study of GB0139 in Idiopathic Pulmonary Fibrosis Recruitment Remains on Track Despite COVID-19 Crisis

Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced that it has recruited more than 150 patients in its Phase 2b GALACTIC-1 study of GB0139 in Idiopathic Pulmonary Fibrosis.

May 6, 2020
·
2 min read
Business

OssDsign Appoints VP of Sales for OssDsign USA, Inc to Drive Continued Growth in the Company’s Largest Market

OssDsign announces the appointment of Eric Patermo as VP of Sales for OssDsign USA, Inc, a wholly owned subsidiary of OssDsign AB.

May 6, 2020
·
3 min read
Deals

C-RAD AB - Interim Report January - March 2020

The first quarter of 2020 generated solid results, despite being a period where unexpected events played a role.

May 6, 2020
·
4 min read
FDA Grants MIV-818 Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma

Medivir AB announced that the U.S. Food and Drug Administration has granted orphan drug designation to MIV-818 for the treatment of patients with hepatocellular carcinoma, the most common type of primary liver cancer.

May 6, 2020
·
2 min read
Pharm Country

Dr. Reddy’s Laboratories Announces the Launch of Desmopressin Acetate Injection USP, 4 mcg/mL in the U.S. Market

Dr. Reddy’s Laboratories Ltd. announced the launch of Desmopressin Acetate Injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic equivalent generic version of DDAVP Injection, 4 mcg/mL, approved by the U.S. Food and Drug Administration.

May 6, 2020
·
4 min read